Dr. Burkitt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UH Cleveland Medical Center
11100 Euclid Ave Department of Medicine-Hematology and Oncology
Cleveland, OH 44106Phone+1 216-844-3951Fax+1 216-844-5234
Education & Training
Sparrow Hospital/Michigan State UniversityResidency, Internal Medicine, 2014 - 2017
Michigan State University College of Osteopathic MedicineClass of 2014
Certifications & Licensure
OH State License 2020 - 2026
DC State License 2017 - 2020
MI State License 2014 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2024 Jun 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 6 citationsSMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck.Nupur Nigam, Benjamin Bernard, Samantha Sevilla, Sohyoung Kim, Mohd Saleem Dar
Cell Reports. 2023-07-25 - 42 citationsPhenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.Kyunghee Burkitt, Mats Ljungman
Molecular Cancer. 2008-03-06 - 37 citationsSMYD3: a regulator of epigenetic and signaling pathways in cancer.Benjamin J. Bernard, Nupur Nigam, Kyunghee Burkitt, Vassiliki Saloura
Clinical Epigenetics. 2021-02-26
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
